Compare HSCS & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HSCS | NXL |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 7.5M |
| IPO Year | 2022 | 2022 |
| Metric | HSCS | NXL |
|---|---|---|
| Price | $2.76 | $0.33 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | 62.2K | ★ 134.3K |
| Earning Date | 03-16-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.84 | 39.76 |
| EPS | N/A | ★ N/A |
| Revenue | $4,319.00 | ★ $301,647.00 |
| Revenue This Year | N/A | $15.52 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 78.78 |
| 52 Week Low | $1.63 | $0.31 |
| 52 Week High | $3.80 | $2.00 |
| Indicator | HSCS | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 62.76 | 40.60 |
| Support Level | $2.61 | $0.33 |
| Resistance Level | $2.76 | $0.50 |
| Average True Range (ATR) | 0.22 | 0.03 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 82.99 | 8.33 |
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.